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S278 Poster Session Itheir incidence and risk-factors following fludarabine (F)-based
RIC and RTC has not been well defined, due to still limited fol-
low-up after these novel regimens. We retrospectively reviewed
data of 931 patients (pts) given allogeneic SCT over a 12 year pe-
riod to identify pts with secondary malignancies. Conditioning
regimens included standard MAC (n 5 257, TBI-based in 111),
F-based RIC [n 5 449, including F with intermediate-dose busul-
fan, (FB2), and F with melphalan (FM)] or F-based RTC
[n 5 225, including F with high-dose busulfan, (FB4), and F
with treosulfan (FT)]. 21 pts had secondary malignancies including
squamous cell carcinoma of the skin (n 5 5), penis (n 5 1) vagina
(n 5 1), tongue (n 5 1) and esophagus (n 5 2), colon cancer (n 5
3), breast cancer (n 5 2), pancreatic cancer (n 5 2), metastatic can-
cer of unknown primary (n 5 1), melanoma (n 5 1), metastatic
sarcoma (n 5 1), Kaposi sarcoma (n 5 1). In all, 5 pts had meta-
static or locally advanced solid tumor at presentation. The median
age at SCT was 53 years (29-70). 19 pts were given F-based RIC/
RTC and none had TBI. The median time from SCT to diagnosis
of second malignancy was 49 months (7 months-11.5 years). 17 pts
had prior cGVHD, 10 moderate-severe and 14 were still on im-
munosuppressive therapy at the diagnosis of secondary malig-
nancy. The 10-year cumulative incidence of secondary
malignancy was 5.3% (95%CI, 3.2-8.7%). It was 2.2% after
BuCy, 8.8% after FB2, 5.5% after FM, 7.8% after FB4 and
5.5% after FT (p 5 0.05 for BuCy Vs. RIC/RTC). Multivariate
analysis identified RIC/RTC and moderate-severe cGVHD as ad-
verse prognostic factors, HR 5.9 (p 5 0.03) and 2.7 (p 5 0.04), re-
spectively. Pts were treated with surgery for localized tumors and
with chemo-radiotherapy or palliative therapy for metastatic dis-
ease. Currently, 17 pts are alive and 4 died, all of them had ad-
vanced solid tumor at presentation. The cumulative incidence of
death due to secondary malignancy was 1.6% at 10 years after
SCT. In conclusion, secondary malignancies are rare but signifi-
cant complication after allogeneic SCT. Curative approach is fea-
sible in a subset of pts. The combination of F and intermediate to
high-dose alkylating agent may be associated with higher risk for
second malignancies than standard therapy with high-dose alkyla-
tors and/or TBI. Larger registry studies with more events are
needed to confirm these observations.202
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Background: Respiratory syncytial virus (RSV) infection can
cause severe pneumonia after HCT. Although there are many
reports about early clinical outcomes after RSV pneumonia,
late sequelae are less well characterized. Therefore, we investi-
gated the late pulmonary function effects of RSV pneumonia af-
ter HCT.
Patients andMethods:HCT recipients who had RSV pneumonia
(radiographic signs and BAL positive for RSV by PCR, DFA or
culture) between 1/1990 and 3/2010 and survived for at least 1
month were retrospectively reviewed. Patients who had pulmonary
function tests (PFTs) at the time of both pre- and post- (day
60625 and/or 1 year680 days) RSV pneumonia were analyzed.
Airflow obstruction was defined as FEV1/FVC\0.7,
FEV1#75%, and FEV1 decrease of $10% according to the mod-
ified NIH guidelines. All patients received aerosolized ribavirin
(RBV) +/- palivizumab.
Results: A total of 28 patients had RSV pneumonia a median of
29.5 days after HCT (range, 9- 1515 days) and survived for at least
1 month. Median patient age was 37 years (range, 10- 67); 27/28
were allograft recipients. Survival at 100 days and 1 year after
RSV pneumonia was 89.3% and 78.6%, respectively; all deaths
were unrelated to RSV (5 died of non-respiratory causes and one
with respiratory failure due to bronchiolitis obliterans). PFTs atday 60 showed significant decreases of %FEV1 and %DLCO com-
pared with before RSV pneumonia (29.5%613.0, p 5 0.003,
224.0%618.2, p\ 0.001, respectively). Pulmonary function at 1
year after RSV pneumonia was also significantly decreased when
compared to baseline (%FEV1: 26.9%612.0, p 5 0.049, %
DLCO: 216.7%621.2, p 5 0.01) but not significantly improved
compared with day 60 measurements. Seventeen patients received
palivizumab in addition to aerosolized RBV in a non-randomized
fashion (there were no significant differences in patient age, acute
and chronic GVHD, or pretransplant PFTs between patients
who did and did not receive palivizumab). Analysis stratified by
palivizumab use did not significantly affect the PFT observations.
Airflow obstruction at 1 year post RSV pneumonia was detected
in 4 of 16 patients. Palivizumab use did not affect the incidence
of airflow obstruction (20% with palivizumab and 33% without,
p 5 0.6).
Conclusions: Long term survivors of RSV pneumonia after HCT
may be at risk for persistent airflow abnormalities. The addition of
palivizumab did not appear to improve late pulmonary function in
this relatively small retrospective study.203
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Hematopoietic stem cell transplantation (HSCT) is used in-
creasingly as a curative therapy in children with malignancies.
However, survivors of HSCT are at risk for disease recurrence
and life-threatening complications. The risk for late mortality
(.2 years) after autologous and allogeneic HSCT has not been
well reported in children. The aim of this population-based ret-
rospective cohort study was to assess late mortality in children
(age 0-18 y-o) who underwent a HSCT in the province of
Ontario, Canada. Nearly all of the province’s pediatric transplan-
tations are performed at a single center (SickKids). Indication for
HSCT, type of transplant, donor source and survival were deter-
mined via a record linkage between the SickKids’ transplant da-
tabase and POGONIS, the provincial pediatric cancer registry.
Mortality information contained in POGONIS is captured at
the time of death in hospital, or by record linkage to the provin-
cial mortality file. Records of all 756 children who were Ontario
residents with a malignancy and underwent HSCT at SickKids
between 1985-2009 were retrieved. Underlying diagnoses were
leukemia (N 5 412), lymphoma (N 5 82), CNS tumor (N 5
55), neuroblastoma (N 5 150), sarcoma (N 5 41) and other
(N 5 16). 372 children underwent allogeneic HSCT and 384 un-
derwent autologous HSCT. Among the allogeneic HSCT group,
226 (60.8%) received related donor HSCT. Overall, 479 children
(63.4%) survived for at least 2 years after HSCT. The median
follow-up of these 479 survivors was 9.98 years. Of these 479
survivors, 98 (20.5%) subsequently suffered a late death. A
greater proportion of patients who underwent autologous
HSCT had a late death (64/251; 25.5%) than patients post allo-
geneic HSCT (34/228; 14.9%). In a multivariate analysis of pa-
tients who underwent autologous HSCT, males had increased
risk of death compared to females (HR 5 2.0, 95% CI:1.12-
3.59), and patients treated for neuroblastoma had a greater risk
of death than those treated for leukemia (HR 5 10.0, 95%
CI:2.78-36.2). Among patients treated with allogeneic HSCT,
none of gender, donor source (related vs. unrelated), age at trans-
plant or underlying diagnosis was associated with increased late
mortality.
In conclusion, children with cancer who are treated with a HSCT
continue to be at risk for premature death even if they survive for 2 or
more years after their transplant. Further investigation will focus on
examining the contributions of treatment toxicity and disease recur-
rence to late mortality.
